Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGX201 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BDP 3 mg | EXPERIMENTAL | 1 mg TID |
| BDP 6 mg | EXPERIMENTAL | 2 mg TID |
| BDP 9 mg | EXPERIMENTAL | 3 mg TID |
| BDP 12 mg | EXPERIMENTAL | 4 mg TID |
| Name | Type | Description |
|---|---|---|
| SGX201 (delayed release beclomethasone 17,21-dipropionate) | DRUG | Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy. |
Inclusion Criteria: * Primary rectal cancer * Planned course of conventional neoadjuvant radiation therapy before surgery * Scheduled to receive chemotherapy * \>/= 18 years of age * Negative pregnancy test Exclusion Criteria: * History of acute or chronic regional enteritis or inflammatory bowel...
SGX201 is an investigational small molecule developed by Soligenix, Inc. (ticker SNGX). It is a delayed release formulation of beclomethasone 17,21-dipropionate being studied for enteritis, a gastrointestinal condition. It has completed a Phase 1 clinical trial and is not approved for commercial use.
SGX201 is being developed for enteritis, specifically for the prevention of acute enteritis in patients with rectal cancer. It is a delayed release formulation designed to deliver beclomethasone 17,21-dipropionate to the gastrointestinal tract. The program remains investigational and has completed one Phase 1 trial.
SGX201 is developed by Soligenix, Inc., a biopharmaceutical company that trades under the ticker symbol SNGX. Soligenix is the sponsor of the clinical program evaluating delayed release beclomethasone 17,21-dipropionate for enteritis in rectal cancer patients.
SGX201 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials currently listed. The drug is investigational and has not been approved by the FDA for any indication.
SGX201 has been evaluated in one completed Phase 1 trial, NCT01073384, titled a dose ranging study of delayed release beclomethasone for prevention of acute enteritis in patients with rectal cancer. The trial enrolled 16 participants in the United States and was randomized and controlled.
Yes. SGX201 is the development code for delayed release beclomethasone 17,21-dipropionate. The two names refer to the same investigational product from Soligenix, Inc. (ticker SNGX), a small molecule formulation being studied for enteritis in rectal cancer patients.